NOTE OF CONCERN

It has been brought to our attention that Figure 10B of “Inhibition of Platelet-Derived Growth Factor B Signaling Enhances the Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Multiple Models of Ocular Neovascularization,” by Nobuo Jo, Carolina Mailhos, Meihua Ju, Eunice Cheung, John Bradley, Kazuaki Nishijima, Gregory S. Robinson, Anthony P. Adamis, and David T. Shima (Volume 168, pages 2036–2053 of the June 2006 issue of The American Journal of Pathology) contains data errors, specifically the duplication of fluorescent images between the Prevention (A) and Regression (B) data points. The matter was reviewed by the journal’s Editors.

Corresponding author Dr. Shima brought this matter to the attention of the Editors. Dr. Shima states that “this was a genuine error, and we are confident in the actual quantitative data presented in the figure. Not only have other investigators reproduced combination data,1 we also presented in the article another experiment performed in a distinct set of studies using Gleevec (imatinib) as the PDGF (platelet-derived growth factor) antagonist. Finally, the combination therapy approach has been validated in a Phase 2b proof-of-concept study in neovascular AMD (age-related macular degeneration) patients and is currently in Phase 3 clinical trial (https://clinicaltrials.gov/ct2/home, accession number NCT01940900).”

The authors report that they no longer have access to the original data, which was held by their employer Eyetech Research Center (Lexington, MA); Eyetech Research Center has since gone through several acquisitions.

Reference